6 results about "Hypromellose phthalate" patented technology

The invention discloses micro-plastic adsorption chewing gum for a digestive system and a preparation method thereof.The chewing gum comprises an oral cavity adsorption layer, a transition protection layer, an intestinal tract stabilizing layer and a bionic gastric mucosa core layer which are sequentially arranged from outside to inside, and the oral cavity adsorption layer is a film prepared from chitosan microspheres, gutta-percha and nano activated carbon; the transition protection layer is a film prepared from a hydroxypropyl methylcellulose phthalate ethanol solution, the intestinal tract stabilizing layer is a film prepared from PLGA and dichloromethane, and the bionic gastric mucosa core layer is an elastic film prepared from silicone rubber and aluminum hydroxide micro powder. Through the triple design of time-controlled dissolution of the transition layer, mechanical locking of the gum-based grid and physical bottom wrapping of the core layer, it can be ensured that microplastics adsorbed by the oral cavity layer are not released again even though the oral cavity layer is dissolved in the stomach, and the whole process from the oral cavity to discharge is safe.

The present invention provides a solid dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof and a carrier. The carrier material includes polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silica, hydroxypropyl methylcellulose (HPMC), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, acrylic resin, hydroxypropyl cellulose (HPC), povidone, copovidone, ethylcellulose, polyoxyethylene glycol, hypromellose acetate succinate (HPMCAS), hypromellose phthalate (HPMCP), or a combination thereof.

The application belongs to the technical field of medicine, and particularly relates to a self-releasing microcapsule for intestinal sampling and application thereof. The self-releasing microcapsule comprises a capsule cavity, a capsule shell, a sealing member and a coating. The capsule shell is provided with a sampling hole, the capsule cavity is internally provided with sampling hydrogel for absorbing sample fluid, the sealing member is arranged in the capsule cavity between the sampling hydrogel and the sampling hole, wherein the expansion of the sampling hydrogel in the capsule cavity presses the sealing member to engage with the sampling hole to seal the capsule cavity, and the coating is arranged on the surface of the capsule shell. The coating comprises the following coating materials in parts by weight: 15-20 parts of hydroxypropyl methyl cellulose phthalate, 25-30 parts of Eudragit L100, 8-12 parts of algal extract, 1-3 parts of polyethylene glycol and 1-2 parts of talc. The self-releasing microcapsule can be used for precise sampling of the colon.

The application discloses albendazole and ivermectin premix and a preparation method thereof. The premix comprises albendazole 8-15%, ivermectin 0.2-0.4%, double-layer inclusion carrier 20-30% and various auxiliary materials in percentage by mass. The application adopts the double-layer inclusion carrier formed by inner layer hydroxypropyl-beta-cyclodextrin and outer layer hydroxypropyl methylcellulose phthalate and povidone K30 to form an enteric barrier. The preparation method comprises the steps of inner layer inclusion, outer layer dispersion, mixing and granulation. The relative bioavailability of the premix reaches 203%-221%, the pig ascarid drive rate is 98.7%-99.5%, the scabies mite negative conversion rate is 98%-100%, the diarrhea incidence is only 2%-3%, the premix is safe for pregnant sow groups, and no adverse reactions such as abortion, premature birth and loss of appetite occur in all test pigs during the test period. The problems of uneven mixing, low bioavailability and large side effects of traditional preparations are solved, and the premix is suitable for livestock and poultry parasite prevention and treatment.

The invention relates to the technical field of biological pharmacy, in particular to an antibody targeted modified double-bacterium-prebiotic delivery system as well as a preparation method and application thereof. VCAM-1 antibody fragments are modified on AKK bacteria and bifidobacterium lactis Probio-M8, fructo-oligosaccharide and inulin are used as prebiotics, metabolism of probiotics is improved, colonization of the probiotics in intestinal tracts is promoted, and finally, hydroxypropyl methylcellulose phthalate (HPMCP) enteric coating is used for coating, so that the content of the probiotics in the intestinal tracts is increased, and the content of the probiotics in the intestinal tracts is increased. And constructing to obtain the antibody targeted modified double-bacterium-prebiotic delivery system, namely V-PM8-Am-FI-HPMC. The V-PM8-Am-FI-HPMC provided by the invention can synchronously realize intestinal flora regulation and control, lipid metabolism balance, inflammation inhibition, ischemia improvement and blood vessel anti-calcification, finally realizes the purpose of treating and / or improving atherosclerosis, and ensures targeting and safety at the same time.

This invention relates to the field of biopharmaceutical technology, and in particular to an antibody-targeted modified dual-strain prebiotic delivery system, its preparation method, and its applications. This invention modifies VCAM-1 antibody fragments onto *AKK* bacteria and *Bifidobacterium lactis* Probio-M8, then utilizes fructooligosaccharides and inulin as prebiotics to enhance probiotic metabolism and promote intestinal colonization. Finally, it coats the system with hydroxypropyl methylcellulose phthalate (HPMCP) enteric coating to construct the antibody-targeted modified dual-strain prebiotic delivery system—V-PM8-Am-FI-HPMC. The V-PM8-Am-FI-HPMC provided by this invention can simultaneously achieve intestinal flora regulation, lipid metabolism balance, inflammation suppression, ischemia improvement, and vascular anti-calcification, ultimately achieving the purpose of treating and / or improving atherosclerosis, while ensuring targeting and safety.